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Background: We investigated the pharmacokinetics of etoposide (ETP) to reduce the inter-individual variations of ETP
concentrations in patients with acute leukemia who underwent allogeneic hematopoietic stem cell transplantation.
We also carried out an in vivo study using rats to verify the dose adjustment.
Methods: This study included 20 adult patients. ETP was administered intravenously at a dose of 15 mg/kg once
daily for 2 days (total dose: 30 mg/kg) combined with standard conditioning of cyclophosphamide and total body
irradiation. In an in vivo study using rats, ETP was administered intravenously at a dose of 15 mg/kg or an adjusted
dose. The ETP plasma concentration was determined by using HPLC. The pharmacokinetic parameters were estimated
by using a 1-compartment model.
Results: The peak concentration (Cmax) of ETP and the area under the plasma concentration-time curve (AUC) of ETP
differed greatly among patients (range of Cmax, 51.8 - 116.5 μg/mL; range of AUC, 870 - 2015 μg · h/mL). A significant
relationship was found between Cmax and AUC (R = 0.85, P < 0.05). Distribution volume (Vd) was suggested to be one
of the factors of inter-individual variation in plasma concentration of ETP in patients (range of Vd, 0.13 - 0.27 L/kg), and
correlated with Alb and body weight (R = 0.56, P < 0.05; R = 0.40, P < 0.05 respectively). We predicted Vd of rats by body
weight of rats (with normal albumin levels and renal function), and the dose of ETP was adjusted using predicted Vd.
In the dose adjustment group, the target plasma ETP concentration was achieved and the variation of plasma ETP
concentration was decreased.
Conclusion: The results suggested that inter-individual variation of plasma concentration of ETP could be reduced by
predicting Vd. Prediction of Vd is effective for reducing individual variation of ETP concentration and might enable a
good therapeutic effect to be achieved.
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Allogeneic stem cell transplantation (allo-SCT) has been
used to treat patients with hematological malignancies.
High-dose intravenous etoposide (ETP) is commonly
used with a standard conditioning regimen of cyclophos-
phamide (CY) and total body irradiation (TBI) [1–6].
However, it has been reported that the pharmacokinetic
parameters of ETP were highly variable between individ-
uals [7]. There have been many studies on the phar-
macokinetics (PK) of ETP but only a few studies on
leukemia patients who received high-dose ETP as a con-
ditioning regimen and underwent allo-SCT [8, 9]. More-
over, the optimal dose of ETP has not been clarified.
In this study, we focused on PK and dose adjustment
of ETP in adult patients with acute leukemia and also
verified the dose adjustment in experimental rats based
on the PK parameters to reduce large variations of
plasma ETP concentration.
Methods
Patients and pharmacokinetic analysis
Patients
PK of ETP was evaluated in 20 patients who underwent
allo-SCT using a conditioning regimen of medium-dose
ETP + CY + TBI between April 2008 and January 2013 at
Hokkaido University Hospital. A summary of the charac-
teristics of the patients is shown in Table 1. Both the
Protocol Review Committee and the Institutional Review
Board of Hokkaido University Hospital approved the
study. Written informed consent was obtained from all
of the patients.
Conditioning regimen and graft-versus-host disease (GVHD)
prophylaxis
All patients received the same conditioning regimen of
medium-dose ETP + CY + TBI, which consisted of ETP
at a dose of 15 mg/kg once daily administered intraven-
ously (i.v.) over 3 h for 2 days (total dose: 30 mg/kg) and
CY at 60 mg/kg once daily administered i.v. over 3 h for
2 days (total dose: 120 mg/kg) followed by 12 Gy of TBI
delivered in 4 or 6 fractions for 2 or 3 days, as reported
previously [10–13]. GVHD prophylaxis was provided
with short-term methotrexate and cyclosporine (CSP) or
tacrolimus (TAC) according to the physician’s selection.
Blood samples of patients
Blood samples were drawn before the start of ETP infu-
sion (blank plasma) and at 1, 3, 6, 10, 24, 25, 27, 30, 34,
44, 68, and 92 h after the first infusion. The samples
were collected into tubes containing heparin. The sam-
ples were centrifuged at 750 × g for 10 min at 4 °C to
obtain plasma, and the plasma was frozen at -20 °C until
analysis. All patients gave informed consent and agreed
to the multiple blood sampling procedure.Analytical procedure
ETP plasma concentration was determined by using
HPLC. Analytical ETP was purchased from LKT
Laboratories Inc. (St. Paul, MN, USA). It was dissolved
in dimethyl sulfoxide (DMSO) (stock concentration:
20 mg/mL) and stored at -20 °C. Acetonitrile, dichloro-
methane, and methanol were of liquid chromatographic
grade. Control plasma was provided by Japanese Red
Cross Blood Center (Hokkaido, Japan) and stored at -20 °C.
The internal standard, diphenyl hydantoin (DPH) was
purchased from Wako Pure Chemical Industries, Ltd.
(Osaka, Japan). ETP plasma concentration was deter-
mined by the method of kato et al. [14]. Briefly, 20 μL of
DPH at a concentration of 100 μg/mL (in methanol),
1 mL of distilled water and 200 μL of plasma were added
to a glass test tube with a screw cap. After 5 mL of dichlo-
romethane had been added, the mixture was shaken for
15 min and then centrifuged at 750 × g for 5 min. Four
mL of the dichloromethane layer was evaporated to dry-
ness at 40 °C in a vacuum evaporator. The residue was
redissolved in 200 μL of the mobile phase of HPLC and
was subjected to HPLC. The injection volume of a sample
was 40 μL. The HPLC system consisted of an L-7110
pump, L-7300 column oven, L-7420 UV-VIS detector, and
D-2500 integrator (HITACHI, Tokyo, Japan). The column
was an Inersil ODS-4 (100 mm× 2.1 mm i.d., 3 μm)
(YOKOHAMARIKA CO., Yokohama, Japan). A mobile
phase containing methanol/distilled water/acetonitrile
(42.7: 55: 2.3, v/v/v) was used at a flow rate of 0.4 mL/min.
The detector was monitored at 229 nm.
Pharmacokinetic analysis
The pharmacokinetic parameters were estimated by
using a 1-compartment model. The peak concentration
(Cmax) and the trough concentration (Cmin) of ETP in
plasma were obtained directly from the analytical data.
The volume of distribution (Vd) was calculated as Dose/
C0 (Cmax). The elimination rate constant (Kel) was calcu-
lated by log-linear regression of ETP concentration data
during the elimination phase. The clearance (CL) was
calculated as Kel × Vd. The area under the plasma
concentration-time curve (AUC) was calculated by the
trapezoidal rule. Mean values of Vd on the first day and
second day were used for subsequent investigation.
Experimental animals and pharmacokinetic analysis
Animals and treatment
Male Wistar rats were obtained from Hokudo Co., Ltd.
(Sapporo, Japan). The experimental protocols were
reviewed by the Animal Care Committee in accordance
with the Guide for the Care and Use of Laboratory
Animals. ETP for intravenous infusion was purchased
from Sandoz (Tokyo, Japan). ETP was diluted in normal
saline. ETP solution was administrated intravenously at
Table 1 Characteristics of the patients (n = 20)
Mean ± S.D. Median Range
Age (year) 31.8 ± 7.0 31 18 – 44
Sex (male/female) 15/5
Body Weight (kg) 67.0 ± 12.5 65.0 45.5 – 91.8
Body surface area (m2) 1.8 ± 0.2 1.8 1.4 – 2.1
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Alb (g/dL) 4.0 ± 0.4 4.0 2.8 – 4.9
T-pro (g/dL) 6.0 ± 0.4 5.8 5.4 – 7.0
BUN (mg/dL) 10.3 ± 3.0 10.5 5.0 – 15.0
Scr (mg/dL) 0.6 ± 0.2 0.6 0.3 – 1.0
T-bil (mg/dL) 0.7 ± 0.3 0.7 0.4 – 1.7
AST (IU/L) 35.0 ± 31.4 21.0 9.0 – 125
ALT (IU/L) 45.6 ± 54.6 32.0 5.0 – 251
ALL indicates acute lymphoblastic leukemia, AML acute myelogenous leukemia, ANKL aggressive NK cell leukemia, SCT stem cell transplantation, CR complete
remission, MRD HLA–matched related donor, MUD HLA-matched unrelated donor, MMRD mismatched related donor, MMUD mismatched unrelated donor,
CSP cyclosporin A, MTX methotrexate, TAC tacrolimus, Alb albumin, T-pro total protein, BUN blood urea nitrogen, Scr serum creatinine, T-bil total bilirubin,
AST asparatate aminotransferase, ALT alanine aminotransferase
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(before the start of ETP infusion (blank plasma) and at
0.017, 0.05, 0.25, 0.75, 1.5, 3, and 6 h after infusion), rats
were anesthetized with diethyl ether, and whole blood
was collected from the jugular vein. Plasma was ob-
tained by centrifugation at 750 × g for 10 min at 4 °C.
The rats were killed by exsanguination after blood col-
lection. ETP plasma concentration was determined byHPLC as described above. PK parameters were deter-
mined as described above.
Statistical analysis
Student’s t-test was used to determine the significance of
differences between two group means. Pearson’s test was
used to determine correlations. Predictability of Vd was
calculated with stepwise regression analysis using JMP®
Fig. 1 Plasma concentration of ETP in patients after i.v. administration
of ETP over 3 h at a dose of 15 mg/kg once daily for 2 days (n = 20)
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significance was defined as P < 0.05.
Results
Results for the patients
Pharmacokinetic analysis of ETP in patients
The plasma concentration versus time curve and the phar-
macokinetic parameters after intravenous administration
of ETP are shown in Fig. 1 and Table 2, respectively. Mean
Cmax on the first day was 74.9 μg/mL (median: 77.4, range:
51.8 - 116.5 μg/mL). Mean AUC0-92h was 1332 μg · hr/mL
(median: 1282, range: 870 - 2015 μg · h/mL). Mean values
of Vd on the first day and second day were 0.20 L/kg
(median: 0.20, range: 0.13 - 0.28). A significant relationship
was found between Cmax (day1) and AUC0-92h (R = 0.85,
P < 0.05). Vd was correlated with Alb and body weight
(R = 0.56, P < 0.05; R = 0.40, P < 0.05 respectively).
Results of experiments using rats
Pharmacokinetic analysis of ETP in rats
We investigated the pharmacokinetic parameters in rats
(with normal Alb levels and renal function). The experi-
mental rats were divided into 3 groups based on the age
of rats [5 weeks (control), 7 weeks and 10 weeks] and were
intravenously administered ETP at a dose of 15 mg/kg.
Table 3 shows the pharmacokinetic parameters of ratsTable 2 Pharmacokinetic parameters of ETP after administration a
patients (n = 20)
Parameter Day 1
Mean ± S.D. Median
Cmax (μg/mL) 74.9 ± 17.0 77.4
Cmin (μg/mL) 3.9 ± 2.5 3.7
Vd (L/kg) 0.20 ± 0.05 0.19
Kel (h–1) 0.15 ± 0.04 0.14
CL (mL/h/kg) 30.9 ± 14.5 24.5
AUC0-24 h or AUC24–44 h (μg・h/mL) 634 ± 154 611
AUC0-92 h (μg・h/mL) 1332 ± 315 1282
Vd indicates volume of distribution, Kel elimination rate constant, CL clearance, AUCafter infusion. Cmax and AUC were significantly higher in
the groups of 7 weeks and 10 weeks than in the group of
5 weeks (control). Vd in the group of 10 weeks were lower
than those in the group of 5 weeks. Kel was not signifi-
cantly different among the 3 groups of rats.
Dose adjustment of ETP in rats
There was a positive correlation between body weight
and Vd of ETP in rats (linear regression equation: Vd (L) =
0.0001 × body weight (g) + 0.0259, R = 0.82, P < 0.05).
Therefore, we predicted Vd from the body weights of
rats and calculated the dose by the following formula:
dose (mg) = Vd (L) × Cmax (μg/mL) to achieve target
Cmax (60 μg/mL). We set a target ETP concentration to
60 μg/mL because the mean Cmax of ETP in the group of
rats administered 15 mg/kg was 57 μg/mL. Cmax of ETP
in the group of rats administered 15 mg/kg increased with
increase in body weight (Fig. 2 (a)). On the other hand,
the group of rats administered the adjusted dose achieved
the target Cmax (Fig. 2 (a)). Moreover, when comparing
the AUC at this time, the variation of ETP concentration
was decreased in the adjustment group (Fig. 2 (b)).
Discussion
Although the standard conditioning regimen of CY + TBI
has been widely used before allo-SCT, the rate of mortality
due to relapse is high and the results of treatment are not
satisfactory [15–20]. Therefore, various intensified condi-
tioning regimens, some of which used ETP combined with
CY + TBI, have been developed. Many studies including
studies in which ETP (60 mg/kg) was combined with CY
and TBI (ETP + CY + TBI) showed a low relapse rate but
high rates of toxicity and transplant-related mortality
[1–6]. We previously reported excellent outcomes for
patients who received a medium-dose ETP (30 mg/kg) +
CY + TBI regimen at Hokkaido University Hospital in
Japan [10, 11] and superior survival to that in patients
who received CY +TBI retrospectively [12]. We also con-
ducted a prospective phase II study. In that study, 1-year
overall survival was 80.8 % (95 % Cl = 66.0 - 88.7 %). Not a dose of 15 mg/kg once daily over 3 h for 2 days in
Day 2
Range Mean ± S.D. Median Range
51.8 – 116.5 77.5 ± 12.9 75.8 61.6 – 106.0
0.2 – 9.1 6.2 ± 3.7 5.4 1.6 – 16.1
0.12 – 0.29 0.20 ± 0.04 0.20 0.14 – 0.27
0.10 – 0.29 0.14 ± 0.03 0.14 0.07 – 0.20
14.2 – 72.6 29.0 ± 8.5 27.4 11.3 – 45.5
423 – 1021 612 ± 126 586 424 – 852
870 – 2015
area under the plasma concentration–time curve
Table 3 Pharmacokinetic parameters of ETP after intravenous
administration at a dose of 15 mg/kg in rats
5 weeks (control) 7 weeks 10 weeks
120 – 150 g 220 – 230 g 320 – 355 g
AUC (μg・h/mL) 12.8 ± 0.33 15.8 ± 1.21* 20.4 ± 3.01*
Cmax (μg/mL) 49.0 ± 9.73 51.7 ± 4.41 71.8 ± 7.57*
Vd (L/kg) 0.32 ± 0.07 0.29 ± 0.03 0.21 ± 0.02*
Kel (h–1) 1.72 ± 0.26 1.80 ± 0.10 1.84 ± 0.38
CL (L/h/kg) 0.54 ± 0.12 0.52 ± 0.06 0.39 ± 0.10*
Each value is the mean ± S.D. of 3 - 4 measurements
*Significantly different from control at p <0.05
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cidences of relapse and non-relapse mortality at 1-year
post SCT were 10.0 and 14.0 %, respectively [13]. These
data indicated that the addition of ETP was important for
outcomes; however, there have been no study on PK of
medium-dose ETP in adult patients with leukemia.
In this study, we focused on the PK of ETP with the aim
of establishing the optimal dosage of ETP. Firstly, the
plasma concentration and pharmacokinetic parameters of
ETP in patients who received medium-dose ETP were de-
termined. In most studies, 2-compartment models were
used for PK analysis of ETP [21, 22]. However, we con-
sider that α-phase of etoposide is almost completed at the
end of the administration because etoposide administered
over 3 h and a semi-logarithmic plot of plasma concentra-
tion versus time appear as a single straight line. Therefore,
we used 1- compartment model for analysis.
It was found that the plasma concentrations of ETP dif-
fered greatly among patients (Fig. 1, Table 2). The plasma
concentrations of ETP should normally be about the same
in all patients. Therefore, factors that account for the
inter-individual variation in the plasma concentration ofa b
Fig. 2 Comparison of (a) Cmax of ETP and (b) AUC of ETP after intravenou
dose (●) in ratsETP were investigated in this study. It has been reported
that the steady-state concentration and AUC of continu-
ous infusion of ETP were related to its toxicity [7, 23]. In
this study, a significant relationship was found between
Cmax and AUC0-92h (R = 0.85, P < 0.05). Therefore, we
focused on factors that cause the inter-individual variation
of Cmax. Individual differences in Cmax are considered to
be due to variation of Vd because Vd is calculated by the
following equation: Vd =Dose/Cmax. We found that Vd
was correlated with Alb and body weight. Protein binding
is important for PK of ETP. ETP is highly bound to Alb in
plasma and the ratio of protein binding is 93 % [24].
Stewart et al. reported that unbound ETP was significantly
increased in cancer patients compared with that in normal
volunteers [25]. These alterations in protein binding
were significantly related to Alb [25]. A relationship
between the ETP binding ratio and Alb was reported
by Schwinghammer et al. (R = 0.57, P = 0.02) [26].
About 35 % of the administered dose of ETP is excreted
into urine as the parent drug [27]. ETP clearance was sig-
nificantly correlated with serum creatinine (Scr) in previous
studies [28, 29]. In the present study, the renal function of
20 patients is normal range (Scr 0.3 - 1.0 mg/dL). There-
fore, we considered that Vd is important for patients with
normal renal function. The study by Krogh-Madsen [22],
baseline white blood cell count (bWBC) and sex influenced
the PK of ETP. However, in this study, no correlation of
bWBC and sex on PK of ETP. These results show that the
variability of AUC could be reduced to adjust dosages by
predicted Vd in patients with normal renal function.
We have investigated the study using rats whether to
reduce the variation of ETP concentration by dose ad-
justment by prediction of Vd. Our in vivo study in rats
suggested that increase of ETP plasma concentration
was mainly associated with increase of body weights administration of ETP at a dose of 15 mg/kg (△) and at the adjusted
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correlated with Vd (R = 0.82, P < 0.05). Therefore, we
predicted Vd by only body weight of rats and calculated
the dose of ETP so as to achieve a target ETP plasma
concentration (60 μg/mL). As a result, the group of rats
with dose adjustment achieved the target ETP plasma
concentration and the variation of plasma ETP concen-
tration was decreased. These results indicate that body
weight is very important for pharmacokinetic parameters
of ETP, especially Vd.
In the investigation using rats, it was shown that body
weight is very important for Vd and that Vd can be pre-
dicted by body weight. In general, the body surface area
(BSA) is used in dose adjustment of chemotherapy.
However, there was high inter-individual variation in
plasma concentration of ETP, even if dose of ETP was
adjusted based on BSA [21]. In addition, body weight-
based dose has been widely used in conditioning regi-
mens [8, 9, 19]. Therefore, we use body weight to deter-
mine the dosage.
In clinical investigations, we focused on only Vd be-
cause there was a strong correlation between Cmax and
AUC. However, Kel is critical for estimating ETP plasma
concentration as well as Vd. In addition, the target ETP
plasma concentration in medium dose ETP therapy has
not been clarified. According to our preliminary analysis,
ETP plasma concentration ≥ 75.6 μg/mL was associated
with a high mortality rate. However, correlations be-
tween results of pharmacokinetic analysis and clinical
outcomes were not sufficient in this study due to the
small sample size. Further studies are needed to establish
the optimal dose of ETP and confirm correlations be-
tween pharmacokinetic parameters of ETP and clinical
outcomes in different patient populations.Conclusions
The results suggested that inter-individual variation of
plasma concentration of ETP could be reduced by pre-
dicting Vd. Prediction of Vd is effective for reducing
individual variation of ETP concentration and might
enable a good therapeutic effect to be achieved.
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